Journals / Uluslararası Hematoloji-Onkoloji Dergisi / 2008 / Cilt: 18 - Sayı: 4

Management of hepatocelluler carcinoma

Hepatosellüler karsinomda tedavi yaklaşımları

Pages
248–253
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Owing to survival advantage in a phase III trial when comparing to placebo, sorefenib seems to be proming agent in HCC.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Hepatocelluler carcinoma is common especially in Asia and Far East where the incidence of viral hepatitis is very high.
📊
Key Findings & Data:Although, surgical resection is the curative treatment procedure for the disease, presence of cirrhosis hinders the resection at about 90% of patients.
💡
Conclusion & Impact:Owing to survival advantage in a phase III trial when comparing to placebo, sorefenib seems to be proming agent in HCC.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Karsinom · hepatosellüler · Carcinoma

Abstract

Hepatocelluler carcinoma is common especially in Asia and Far East where the incidence of viral hepatitis is very high. Treatment of HCC includes the treatment of underlying chronic liver disease caused by viral hepatitis and the tumor itself. Although, surgical resection is the curative treatment procedure for the disease, presence of cirrhosis hinders the resection at about 90% of patients. Besides, owing to diffuse and multiple lesions, most of the patients are not suitable for the curative resection. Liver transplantation can cure both the underlying chronic liver disease and the HCC. Liver transplantation are performed according to expanded criteria and successful results have been obtained at our center. Local and ablative treatments are put on to the agenda in patients whom are not suitable for surgical intervention. Transarterial chemoembolisation (TACE), percutaneous alcohol injections (PAI) and radiofrequency ablation (RF) are the most common procedures that are effective in small solitary lesions. Systemic chemotherapies are used in the case of extrahepatic dissemination or in patients with unresectable disease. Cisplatin, doxorubicin, etoposite and 5-flourouracil have been used both as a single agent and in combinations but the response rates are limited between 8 to 18%. In this group of patients although the higher response rate was achieved with the combination of cisplatin, interferon-α-2b, doxorubicin and 5-flourouracil (PIAF), no survival advantage was obtained when compared with doxorubicin. This combination has not been accepted as a standard because of its severe morbidity. Recently sorefenib, a Raf kinase intibitor, was shown to be effective in HCC. Owing to survival advantage in a phase III trial when comparing to placebo, sorefenib seems to be proming agent in HCC.

Özet

Hepatosellüler karsinoma (HCC) özellikle viral hepatit insidansı yüksek olan Asya ve Uzak Doğu’da sık görülen bir tümördür. Viral hepatitlere bağlı kronik karaciğer hastalığı zemininde gelişen HCC da tedavi gerektiren sadece tümörün kendisini değil aynı zamanda altta yatan karaciğer hastalığıdır. Cerrahi rezeksiyon, küratif bir yöntem olmasına rağmen sirozun varlığı hastaların %90’nında rezeksiyona engel olmaktadır. Bununla beraber sıklıkla yaygın ya da çoklu lezyonlara rastlanıldığı için, hastalar küratif rezeksiyona uygun olmamaktadırlar. Karaciğer transplantasyonu hem altta yatan kronik karaciğer hastalığının tedavisinde hem de HCC tedavisinde kür sağlayıcı bir tedavidir, merkezimizde genişletilmiş kriterlerle yapılan karaciğer transplantasyonlarda oldukça başarılı sonuçlar alınmaktadır. Cerrahi girişime uygun olmayan hastalarda lokal ablatif tedaviler gündeme gelmektedir. Transarteriel kemoembolisazyon (TACE), perkütan alkol enjeksiyonu (PAE) ya da radyofrekans ablasyon (RF) sık kullanılan yöntemler olup, küçük solid lezyonlarda etkili olabilmektedir. Ekstrahepatik yayılım varlığında, cerrahi rezeksiyona uygun olmayan hastalarda sistemik kemoterapiler kullanılmaktadır. Sisplatin, doksorubisin, etoposit ve 5-Florourasil gibi pek çok ilaç tek başına yada kombine olarak kullanılmış ancak yanıt oranları %8-18 ile sınırlı kalmıştır. Sisplatin, interferon-alfa-2b, doksorubisin ve 5-florourasil (PIAF) kombinasyonu ile bu grup hastalarda yüksek yanıt oranı elde edilmiş olmasına rağmen doksorubisinle karşılaştırıldığında sağ kalım avantajı sağlamadığı görülmüştür. Ciddi morbiditesi olması nedeniyle bu kombinasyonun henüz standart olarak kabul edilmemektedir. Son yıllarda HCC da etkinliği gösterilen bir ajanda, Raf kinaz inhibitörü olan sorafenibdir. Faz III çalışmada plaseboya karşı anlamlı olarak sağ kalım avantajı sağladığı gösterildiğinden dolayı, sorefenib HCC’un tedavisinde umut verici gibi görünmektedir.

🔖

Cite This Article

YILDIRIM, Y., ÖZYILKAN, Ö., KARAKAYALI, H., HABERAL, M. (2008). Management of hepatocelluler carcinoma. Uluslararası Hematoloji-Onkoloji Dergisi, Cilt: 18 - Sayı: 4, 248–253. https://ajindex.com/articles/323066

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (14)

  1. Llovet JM, Fuster J, Bruix J. Intention to treat analysis of surgical treatment for early hepatocelluler carcinoma: Resection versus transplantation. Hepatology 30: 1434-1440, 1999
  2. Miyagawa S, Makuuchi M, Kawasaki S, Kazaku T. Criteria for safe hepatic resection. Am J Surg 169: 589, 1995
  3. Bartlett DL, Carr BI, Marsh JW. Cancer of Liver. In: Cancer, Principles and Practice of Oncology. DeVita VT, Hellman S, Rosenberg SA (eds). 6th ed. Philadelphia, Lippincott-Raven, 2001: 1162-1177
  4. Roayaie S, Schwartz M. Liver resection and transplantation for hepatocelluler carcinoma. In American Society of Clinical Oncology Educational Book. Perry MC (ed). Alexandria, VA 2005; 324-28
  5. Tsuzuki T, Sugioka A, Ueda M, et al. Hepatic resection for hepatocellular carcinoma. Surgery 107: 511, 1990
  6. Grazi GL, Cescon M, Ravaioli M, et al. Liver resection for hepatocelluler carcinoma in cirrhotics and noncirrhotics. Evaluation of clinicopathologic features and comparison of risk factors for long term survival and tumour recurrence in single centre. Aliment Pharmocol Ther 17[suppl2]: 199, 2003
  7. Monden M, Sakon M, Gotoh M, et al. Selection of therapeutic modalities for hepatocelluler carcinoma in patients with multiple hepatic lesions. Cancer Chemother Pharmacol 31: [Suppl]: S 38-44, 1992
  8. Chen WT, Chau GY, Lui WY, et al. Recurrent hepatocelluler carcinoma after hepatic resection: Prognostic factors and long-term outcome. Eur J Surg Oncol 30: 414-420, 2004
  9. Steinmuller T, Jonas S, Neuhaus P. Liver transplantation for hepatocelluler carcinoma. Aliment Pharmacol Ther 17 [Supp 2]: 138, 2003
  10. Freeman RB. Transplantation for heapatocelluler carcinoma: The Milan criteria and beyond. Liver Transp 12 [Suppl 2]: 8-13, 2006
  11. Karakayali H, Moray G, Sozen H, Dalgıc A, et al. Expanded criteria for liver transplantation in patients with hepatocelluler carcinoma. Tranplant Proc 38: 575-578, 2006
  12. Haberal M, Emiroglu R, Karakayali H, et al. Expanded criteria for hepatocellular carcinoma and liver transplantation. Int Surg 92: 110-115, 2007
  13. Lesurtel M, Müllhaupt B, Pestalozzi BC, et al. Transarteriel chemoembolization as bridge to liver transplantation for hepatocelluler carcinoma: an evidence based analysis. Am J Transplant 6: 2644-2650, 2006
  14. Mazzaferro V, Battiston C, Perrone S, et al. Radiofrequency ablation of small hepatocellular carcinoma in cirrhotic patients awaiting liver transplantation: A prospective study. Ann Surg 240: 900-909, 2004. 15